Arbutus Announces Multiple Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2023
11 oct. 2023 08h05 HE
|
Arbutus Biopharma Corporation
Imdusiran data will be highlighted in late breaking presentation WARMINSTER, Pa., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage...
Arbutus to Present AB-729 and AB-836 Data at EASL Congress 2023
07 juin 2023 02h01 HE
|
Arbutus Biopharma Corporation
WARMINSTER, Pa., June 07, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop...
Arbutus to Present AB-729 and AB-161 Data at the Global Hepatitis Summit 2023
18 avr. 2023 16h01 HE
|
Arbutus Biopharma Corporation
Two oral presentations scheduled for Thursday, April 27, 2023 WARMINSTER, Pa., April 18, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical...
Arbutus to Present Seven Scientific Posters at EASL International Liver Congress™ 2022
08 juin 2022 02h05 HE
|
Arbutus Biopharma Corporation
Conference Call & Webcast to discuss new data being presented at EASL ILC 2022 scheduled for June 27, 2022 at 8:00 am ETWARMINSTER, Pa., June 08, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma...